Literature DB >> 11766849

Factors affecting over-the-counter use of aspirin in the secondary prophylaxis of cardiovascular disease.

J Bedson1, T Whitehurst, M Lewis, P Croft.   

Abstract

Little is known about the contribution of over-the-counter (OTC) aspirin to cardiovascular prophylaxis. To investigate this, a two-phase cross-sectional study was carried out in nine general practices in North Staffordshire. In the first phase, all patients with cardiovascular disease (CVD) were identified from computer searches using morbidity registers and drug searches. The search also identfied the subgroup receiving prescribed prophylactic aspirin. In the second phase, a questionnaire was posted to all patients with CVD who were not on prescribed aspirin to establish their current use of OTC aspirin. Overall, 69% of the CVD group used aspirin, with 26% of aspirin being OTC. OTC aspirin use was more common in those aged under 65 years, men, and the more affluent. Also, there were significant differences in OTC aspirin use between the various practices. This study shows that a considerable amount of aspirin is used OTC in those with CVD. Its use is influenced by several factors that could be addressed when considering attempts to improve the overall uptake of aspirin.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11766849      PMCID: PMC1314169     

Source DB:  PubMed          Journal:  Br J Gen Pract        ISSN: 0960-1643            Impact factor:   5.386


  7 in total

1.  Secondary prevention in coronary heart disease: baseline survey of provision in general practice.

Authors:  N C Campbell; J Thain; H G Deans; L D Ritchie; J M Rawles
Journal:  BMJ       Date:  1998-05-09

2.  An audit of discharge medication for secondary prophylaxis post-myocardial infarction.

Authors:  J Richardson; C Truman
Journal:  J Clin Pharm Ther       Date:  1996-12       Impact factor: 2.512

3.  Use of secondary prophylaxis against myocardial infarction in the north of England.

Authors:  M Eccles; C Bradshaw
Journal:  BMJ       Date:  1991-01-12

4.  Increasing prescription of drugs for secondary prevention after myocardial infarction.

Authors:  J Smith; K S Channer
Journal:  BMJ       Date:  1995-10-07

5.  Audit of secondary prophylaxis after myocardial infarction.

Authors:  D L Whitford; A J Southern
Journal:  BMJ       Date:  1994-11-12

6.  Aspirin after myocardial infarction: the importance of over-the-counter use.

Authors:  S Hopper; M Pierce
Journal:  Fam Pract       Date:  1998-04       Impact factor: 2.267

7.  Aspirin for secondary prevention after acute myocardial infarction in the elderly: prescribed use and outcomes.

Authors:  H M Krumholz; M J Radford; E F Ellerbeck; J Hennen; T P Meehan; M Petrillo; Y Wang; S F Jencks
Journal:  Ann Intern Med       Date:  1996-02-01       Impact factor: 25.391

  7 in total
  12 in total

Review 1.  NSAID-associated adverse effects and acid control aids to prevent them: a review of current treatment options.

Authors:  Jørgen Naesdal; Kurt Brown
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

2.  Increased gap density predicts weakness of the epithelial barrier in vivo by confocal laser endomicroscopy in indomethacin-induced enteropathy.

Authors:  Sha Shi; Han Wang; Hui Gao; Zhen Li; Fei-Xue Chen; Xiu-li Zuo; Yan-qing Li
Journal:  Dig Dis Sci       Date:  2014-02-27       Impact factor: 3.199

3.  Cardiovascular prophylaxis with aspirin: costs of supply and management of upper gastrointestinal and renal toxicity.

Authors:  S V Morant; A D McMahon; J G F Cleland; P G Davey; T M MacDonald
Journal:  Br J Clin Pharmacol       Date:  2004-02       Impact factor: 4.335

4.  Discontinuation of low dose aspirin and risk of myocardial infarction: case-control study in UK primary care.

Authors:  Luis A García Rodríguez; Lucía Cea-Soriano; Elisa Martín-Merino; Saga Johansson
Journal:  BMJ       Date:  2011-07-19

5.  Exploring the equity of GP practice prescribing rates for selected coronary heart disease drugs: a multiple regression analysis with proxies of healthcare need.

Authors:  Paul R Ward; Peter R Noyce; Antony S St Leger
Journal:  Int J Equity Health       Date:  2005-02-08

Review 6.  Is ranitidine therapy sufficient for healing peptic ulcers associated with non-steroidal anti-inflammatory drug use?

Authors:  N D Yeomans; L-E Svedberg; J Naesdal
Journal:  Int J Clin Pract       Date:  2006-11       Impact factor: 2.503

7.  Comorbidities affect risk of nonvariceal upper gastrointestinal bleeding.

Authors:  Colin John Crooks; Joe West; Timothy Richard Card
Journal:  Gastroenterology       Date:  2013-03-05       Impact factor: 22.682

8.  Post-diagnostic prescriptions for low-dose aspirin and breast cancer-specific survival: a nested case-control study in a breast cancer cohort from the UK Clinical Practice Research Datalink.

Authors:  Liam J Murray; Janine A Cooper; Carmel M Hughes; Des G Powe; Chris R Cardwell
Journal:  Breast Cancer Res       Date:  2014-04-04       Impact factor: 6.466

9.  Pain medication management of musculoskeletal conditions at first presentation in primary care: analysis of routinely collected medical record data.

Authors:  Mehluli Ndlovu; John Bedson; Peter W Jones; Kelvin P Jordan
Journal:  BMC Musculoskelet Disord       Date:  2014-12-10       Impact factor: 2.362

10.  Validation of low-dose aspirin prescription data in The Health Improvement Network: how much misclassification due to over-the-counter use?

Authors:  Lucía Cea Soriano; Montse Soriano-Gabarró; Luis A García Rodríguez
Journal:  Pharmacoepidemiol Drug Saf       Date:  2015-12-13       Impact factor: 2.890

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.